+1.855.360.3282 Contact Us

How Pharma Harnesses Big Data to Address Unmet Medical Needs


eyeforpharma Philadelphia 2015

How can pharma harness rapid advances in Digital & Big Data technologies to address unmet medical needs?

WHAT: eyeforpharma conferences facilitate collaboration and enable pharmaceutical organizations to become sustainable partners in customer-driven healthcare.  

Ramon Chen, VP of Marketing at Reltio, and representatives of other companies at the leading edge of this dynamic field, will participate in a digital health panel exploring how emerging technologies and information streams can have a hugely beneficial effect on patient programs and outcomes.  

Following its public launch and announcement of Series A funding on March 16, 2015, Reltio will now announce significant early momentum in pharma with medical device companies adopting its Reltio Cloud and built-in data-as-a-service (DaaS). This includes a new partnership with DMD, a pioneer in healthcare digital communications and connectivity, to provide on demand access to the most comprehensive database and up-to-date physician emails directly from within Reltio Data-driven applications. DMD joins Enclarity and Health Market Science (both now LexisNexis), MedPro Systems and DarkMatter2BD as partners delivering their data through Reltio DaaS.

WHY: Just as the pharmaceutical industry is under heavy pressure to reduce R&D costs and speed time to market for new products, new data-driven applications have the potential to drastically alter—and enhance—long-held operating practices.

Easier access to the latest information is at the heart of the ongoing transformation in this critical discipline, and Reltio is paving the way as the creator of life sciences data-driven applications that enable pharmaceutical organizations to be more customer and patient-centric. The company was recently cited by PharmaVOICE as an innovator disrupting the healthcare landscape, alongside such marquee names as Google and GE Healthcare, and analysts at Constellation Research and 451 Research have profiled Reltio’s technology as pioneering and disruptive.

HOW: Enabling the transformation—bringing the benefits of data-driven applications and modern data management to improve the efficiency of clinical trials, commercial operations including product launches that ultimately result in life-saving drugs and medical products—requires close cooperation between life sciences organizations, technology and service providers. Reltio has formed a series of strategic partnerships with companies such as ZS Associates, Cognizant, HighPoint Solutions and others in this field.

WHERE: Hilton Philadelphia at Penn’s Landing 

WHEN: Tue, Apr 7, 2015 from 5-6pm

MEET RELTIO: Please provide your availability to meet one-on-one with a Reltio executive for a more in-depth briefing and demo at eyeforpharma.

Paula Dunne
1-408-776-1400 (office)  1-408-893-8750 (mobile)